

## Supplementary Online Content

Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia: the SAFER randomized clinical trial. *JAMA Pediatr*. Published online March 8, 2021. doi: 10.1001/jamapediatrics.2020.6735

**eTable 1.** Baseline Characteristics (Per-Protocol Population)

**eTable 2.** Subgroup Analyses of Primary Outcome by Subgroups: Age, Salivary CRP, and Detection of Virus/*Mycoplasma* Species

**eTable 3.** Subgroup Analyses of Secondary Outcomes (Binary)

**eTable 4.** Subgroup Analyses of Secondary Outcomes (Count)

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Baseline Characteristics (Per-Protocol Population)

	Short course (intervention) N=122	Standard course (control) N=114
Female sex; n(%)	56(46.7)	39(34.2)
Missing	2	0
Age (year); median (Q1,Q3)	2.52(1.57,4.42)	2.37(1.57,5.12)
Missing	1	0
Respiratory rate at admission (breaths per minute); mean(sd)	30.6(9.05)	31.4(10.9)
Missing	5	2
Pneumonia reported by radiologist; n(%)	86(70.5)	87(76.3)
Baseline salivary CRP, pg/mL	15.3(7.30,73.3)	15.2(7.14,69.9)
Missing	62	51
Baseline NPS positive for a respiratory virus*; n(%)		
RSV	21(23.6)	25(26.6)
Rhino/enterovirus	16(18.0)	13(16.5)
Metapneumovirus	12(13.5)	7(8.9)
Influenza	6(6.7)	5(6.3)
Parainfluenza	7(7.9)	4(5.1)
Adenovirus	4(4.5)	5(6.3)
Negative for all	31(34.8)	28(35.4)
Missing	33	35
Baseline NPS positive for <i>Mycoplasma</i> ; n(%)	4(4.65)	5(6.49)
Missing	36	37

\*column percentages add to more than 100% since individuals can have more than one virus

eTable 2. Subgroup Analyses of Primary Outcome by Subgroups: Age, Salivary CRP, and Detection of Virus/*Mycoplasma* Species

Outcome	Subgroup	N	Short Course (Intervention) n/N(%)	Standard Course (Reference) n/N(%)	Risk difference (95%CI)	Interaction p
Clinical cure; n(%)	Age					0.25
	5-10years	62	19/27(70.4)	30/35(85.7)	-0.12(-0.33,∞)	
	<5 years	189	88/98(89.8)	76/91(83.5)	0.056(-0.037,∞)	
	Salivary CRP					0.83
	Higher ≥30	52	20/24(83.3)	22/28(78.6)	0.016(-0.21,∞)	
	Lower <30	76	33/36(91.7)	34/40(85.0)	0.071(-0.071,∞)	
	Detection of virus/ <i>Mycoplasma</i>					0.15
	Detected	122	57/62(91.9)	50/60(83.3)	0.086(-0.030,∞)	
	Not detected	52	23/26(88.5)	24/26(92.3)	-0.039(-0.20,∞)	

eTable 3. Subgroup Analyses of Secondary Outcomes (Binary)

BINARY outcomes						
Outcome	Subgroup	N	Short Course (Intervention) n/N(%)	Standard Course (Reference) n/N(%)	Risk Difference (95%CI)	Interaction p
Clinical cure not requiring additional intervention	Age					0.71
	5-10years	62	23/27(85.2)	31/35(88.6)	-0.029(-0.029,∞)	
	<5 years	186	92/96(95.8)	82/90(91.1)	0.044(-0.028,∞)	
	Salivary CRP					0.59
	Higher	52	20/24(83.3)	25/28(89.3)	-0.049(-0.049,∞)	
	Lower	76	36/36(100.0)	37/40(92.5)	0.089(-0.25,∞)	
	Detection of virus/ <i>Mycoplasma</i>					0.12
	Detected	120	60/61(98.4)	53/64(82.81)	0.081(-∞,0.20)	
	Not detected	51	22/29(75.86)	25/29(86.21)	-0.10(-∞,0.097)	
Adherence to study medications	Age					0.13
	5-10years	66	23/29(79.3)	33/37(89.2)	-0.16(-0.42, 0.11)	
	<5 years	200	98/105(93.3)	81/95(85.2)	0.088(0.0069, 0.17)	
	Salivary CRP					0.622
	Higher	57	25/28(89.3)	26/29(89.7)	0.015 (-0.18, 0.20)	
	Lower	81	35/37(94.6)	37/44(84.1)	0.087(-0.10, 0.28)	
	Detection of virus/ <i>Mycoplasma</i>					0.645
	Detected	125	62/64(96.9)	54/61(88.5)	0.084(-0.0071, 0.17)	
	Not detected	56	27/28(96.4)	24/28(85.7)	0.18(0.012,0.32)	
Recurrence of respiratory illness after primary outcome visit but before 30-day followup	Age					
	5-10years	62	2/27(7.41)	0/35	0.066(-0.29, 0.42)	0.459
	<5 years	191	8/101(7.92)	12/90(13.3)	-0.048(-0.13, 0.038)	
	Salivary CRP					0.671
	Higher	54	1/26(3.85)	5/28(17.9)	-0.08(-0.44,0.28)	
	Lower	77	3/37(8.11)	4/40(10.0)	-0.014(-0.16,0.13)	
	Detection of virus/ <i>Mycoplasma</i>					0.608
Detected	121	5/63(7.94)	5/58(8.62)	-0.0068(-0.11, 0.092)		
Not detected	51	3/25(12.0)	2/26(7.69)	0.043(-0.12,0.21)		

eTable 4. Subgroup Analyses of Secondary Outcomes (Count)

COUNT OUTCOMES						
Outcome	Subgroup	N	Short Course (Intervention) Median(Q1,Q3)	Standard Course (Control) Median(Q1,Q3)	Incident Rate Ratio (95%CI)	Interaction p
Caregiver absenteeism (caregiver-days)	Age					<0.001
	5-10years	62	3 (1, 9)	3 (0, 6)	1.47 (1.16,1.87)	
	<5 years	183	1 (0, 3)	3 (1, 7)	0.57 (0.49,0.66)	
	Salivary CRP					<0.001
	Higher	52	1 (0, 3)	4 (1, 9)	0.57 (0.43,0.75)	
	Lower	76	2 (1, 4)	3 (0, 7)	0.98 (0.79,1.23)	
Child absenteeism (days)	Detection of virus/ <i>Mycoplasma</i>					<0.001
	Detected	114	1 (0, 3)	3 (0, 9)	0.57 (0.48,0.69)	
	Not detected	48	2 (0, 8)	2 (1, 4)	1.28 (0.94,1.74)	
	Age					0.535
	5-10years	68	1 (1, 1)	1 (1, 1)	1.15 (0.67,2.09)	
	<5 years	212	1 (0,1)	1 (0, 1)	0.92 (0.65,1.31)	
Mild drug adverse reactions (symptom- days)	Salivary CRP					0.361
	Higher	58	0.50 (0, 1)	1 (1, 1)	0.69 (0.35,1.35)	
	Lower	85	1 (0, 1)	1 (0, 1)	0.99 (0.59,1.67)	
	Detection of virus/ <i>Mycoplasma</i>					0.527
	Detected	130	1 (0, 1)	1 (0, 1)	0.80 (0.51,1.27)	
	Not detected	58	1 (0, 1)	0 (0, 1)	1.12 (0.58,2.15)	
Mild drug adverse reactions (symptom- days)	Age					0.218
	5-10years	62	1 (0, 3)	1 (0, 3)	1.15 (0.79,1.65)	
	<5 years	183	1 (0, 3)	1 (0, 3)	0.86 (0.70,1.05)	
	Salivary CRP					0.0487
	Higher	52	1 (0, 4)	1 (0, 3)	1.14 (0.79,1.65)	
	Lower	76	1 (0, 3)	1 (0, 3)	0.72 (0.52,0.99)	
	Detection of virus/ <i>Mycoplasma</i>					0.148

	Detected	101	1 (0, 3)	2 (0,4)	0.80 (0.63,1.03)	
	Not detected	38	1 (0, 3)	0 (0,3)	1.13 (0.76,1.67)	